Immunogenicity of Heptavalent Conjugate Vaccine Against Streptococcus pneumoniae in Premature Babies with Low Birth Weight  by Szynczewska, Ewa & Chlebna-Sokół, Danuta
Pediatrics and Neonatology (2014) 55, 101e107Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.pediatr -neonatol .comORIGINAL ARTICLEImmunogenicity of Heptavalent Conjugate
Vaccine Against Streptococcus pneumoniae
in Premature Babies with Low Birth WeightEwa Szynczewska*, Danuta Chlebna-Soko´1Department of Paediatric Propaedeutics and Metabolic Bone Diseases of Medical University of Lodz,
PolandReceived Jan 31, 2013; received in revised form Jun 4, 2013; accepted Jun 9, 2013
Available online 12 October 2013Key Words
adverse events;
immunogenicity;
low birth weight;
pneumococcal-
CRM197 conjugate
vaccine;
prematurity;
Streptococcus
pneumoniae* Corresponding author. Public Clinic
E-mail address: eszynczewska@gm
1875-9572/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.pedneo.2Background: There are few studies about immunogenicity and safety of heptavalent
pneumococcal-CRM197 conjugate vaccine (PCV7) in low birth weight infants.
Objective: Assessment of immunogenicity following administration of PCV7 in low birth weight
children.
Methods: The PCV7 vaccine was administered to 60 infants divided into two groups: 23 children
with birth weight <1000 g (Group I); and 37 children with birth weight 1000 g (Group II).
Serum was collected four times.
Results: Birth weight of children included in the study ranged from 480 g to 2450 g. The primary
immunization caused an increase in the average concentration of antibodies for all serotypes in
most of the participants, with no significant differences between the groups. However, there
were some differences between various serotypes. Group serotypes 6B and 23F were the least
immunogenic (0.35 mg/mL, Group I vs. Group II e 6B: 78.3% vs. 67,6% pZ 0.371 and 23F: 87%
vs. 83.8% pZ 0.738). Prior to the administration of a booster dose, a significant decrease in anti-
body titer was observed in all children. The last vaccination resulted in an increased concentra-
tion of antibodies in all children in both groups, and the results were significantly higher
compared to those measured following administration of three doses of the vaccine.
Conclusion: PCV7 is immunogenic in childrenwith low, very low, and extremely lowbirthweight.
Serotypes 6B and 23F were the least immunogenic, and serotype 14 proved to be themost immu-
nogenic.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.Hospital Number 4 of Medical University of Lodz, Sporna 36/50, 91-738 qo´dz, Poland.
ail.com (E. Szynczewska).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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102 E. Szynczewska, D. Chlebna-Soko´11. Introduction Children with known immunodeficiencies and diagnosedBiological and immunological immaturity of prematurely
born children promotes infections, which are the most
common cause of hospitalization during the first 2 years of
life. Streptococcus pneumoniae, one of the most common
bacterial pathogens in the world, is one of the most serious
hazards. The microorganism often causes otitis media,
sinusitis, and pneumonia. In addition, following a successful
introduction of mass vaccination against Haemophilus
influenzae type b, it is responsible for the majority of
invasive infections in Poland: sepsis and meningitis.1 More
than 90 serotypes of the bacteria have been identified so
far, based on differences in the properties of bacterial
capsular polysaccharide antigen. All serotypes may be
pathogenic, but seven of them are responsible for about
83% of invasive infections in children younger than 5 years
in the USA and 80% in Europe.2,3 In Poland the rate is 68.7%4
and overall incidence of invasive pneumococcal disease
(IPD) in children aged 0e59 months is 17.6/100,000/year.5
Experiences of recent decades indicate that preterms
and children born with low weight, like other individuals
with immunological deficiencies, should be vaccinated ac-
cording to their chronological age.6,7 However, those chil-
dren may demonstrate an inferior response to vaccine
antigens; hence an assessment of their immune response
seems important.8 Moreover, despite the fact that 10- and
13-valent vaccines are currently available, a high ratio of
children vaccinated with pneumococcal-CRM197 conjugate
vaccine (PCV7) is hampering the assessment of clinical ef-
ficacy of the new, conjugated vaccine in the prevention of
IPD (especially when compared to placebo). The World
Health Organization (WHO) adopted criteria of immunoge-
nicity, compared to PCV7 (immunological response not
inferior to PCV7), as a basis for assessment and registration
of new vaccines.9e11
Most published papers discuss children born at term and
with normal weight.12e14 Only a few of them contain data
on immunogenicity of that vaccine in children born pre-
maturely and with low birth weight.15e19
Because it is known that the distribution of serotypes
and incidence depend on the region and population,12,20,21
we decided to carry out an assessment of the immune
response among Polish children.2. Materials and Methods
The study was conducted in a group of 60 children born with
low birth weight (initially a group of 40, with a further 20
the following year), hospitalized in the Neonate Pathology
Ward of the Department of Pediatric Propedeutics and
Metabolic Bone Diseases of the Medical University of Lodz,
and managed by two outpatient clinics: Prematurity Com-
plications and Neonate Pathology. The University Ethics
Committee approved the research. Evaluation of immuno-
genicity in the same children is planned for the future.
Infants in a stable state of health were administered the
conjugate vaccine against S. pneumoniae, Prevenar
(Wyeth, currently Pfizer, New York, NY, USA), at a dose of
0.5 mL as an intramuscular injection in the lateral thigh.with severe chronic or progressive diseases were excluded
from the analysis. Responders were classified into two
groups, depending on birth weight: Group I included 23
children with birth weight <1000 g; and Group II included
37 children with birth weight 1000 g (21 of whom were
born with weight 1000e1500 g). Vaccinations were planned
in accordance to the Polish Expanded Program of Immuni-
zation: a basic immunization at ages 2 months, 4 months,
and 6 months, and a booster dose at age 16 months, com-
bined with the vaccine against diphtheria, tetanus,
pertussis, polio, and H. influenzae type b. The dose
administered at age 2 months was combined with the vac-
cine against hepatitis B.
Blood (3 mL) was collected from each patient four times:
(1) prior to the first dose of the vaccine (Measurement I);
(2) 4 weeks after the primary vaccination (Measurement II);
(3) prior to the booster dose administration (Measurement
III); and (4) 4 weeks later (Measurement IV). Centrifuged
serum was stored at e22 C. Determination of concentra-
tion of specific immunoglobulin G antibodies against all
seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) included
in the PCV7 vaccine was performed in Statens Serum
Institute, Copenhagen, Denmark, using the enzyme-linked
immunosorbent assay method. The level of antibodies
0.35 mg/mL is considered to be protective against IPD.22
Nonparametric tests were used for statistical analysis,
because distribution of analyzed traits was significantly
different from the normal distribution. The ManneWhitney
U test was used for a comparison of the results obtained
from the two groups. Wilcoxon test was used for the eval-
uation of changes in antibody levels during the study. The
Chi-square test for independence was used, including
Yates’ amendments, and in some cases Fisher exact test
was used for comparison of ratios of children who achieved
protective levels of antibodies and to demonstrate the
relationship between birth weight and the concentration of
antibodies. A null hypothesis was considered rejected when
the computer-calculated level of significance met the
assumption of p <0.05.3. Results
Vaccinations were performed in a total of 60 infants (29
boys, 31 girls). All children were born with a birth weight of
480e2450 g (mean 1284 g), at 24e34 weeks of pregnancy
(mean 30 weeks). The characteristics of patients are shown
in Table 1.
Table 2 summarizes geometric mean antibody concen-
trations against all seven serotypes included in the vaccine
for all children, divided into groups. Concentration of an-
tibodies, first measured prior to the administration of PCV7,
was low for all serotypes. After primary immunization, an
increase in the average concentration of antibodies for all
serotypes was observed in most children, with no significant
differences between groups. However, there were differ-
ences between various serotypes. For both groups the
highest concentration of antibodies was observed for the
serotype 14, and the lowest for serotypes 9V and 4 in Group
I and for serotype 18C in Group II. Prior to the
Table 1 Characteristics of the children in groups sepa-
rated by birth weight.
Characteristics of
the children
Group I (birth
weight <1000 g)
Group II (birth
weight 1000 g)
Number of children 23 37
Gestational age (wk of gestation)
Median 27.7 31.2
Range 24e29 30e34
Sex
Boy 13 16
Girl 10 21
Birth weight (g)
Median 848 1554
Range 480e980 1150e2450
Immunogenicity of PCV7 in LBW preterms 103administration of the booster dosedat age 16 monthsda
significant decrease in antibody titer was observed in all
children. The kinetics of the decrease in antibody concen-
tration were similar in both groups, and they were
serotype-dependent. The last vaccination resulted in
another significant increase in the concentration of anti-
bodies in both groups, and the results were significantly
higher than those measured after the previous three doses
of the vaccine. During the study period, the lowest values
were observed for serotype 4, and the highest for serotype
14. Again, there were no significant statistical differences
between groups. Moreover, a variation in immune response
was observed, depending on the time of evaluation of an-
tibodies (Figure 1). The average antibody level during each
period of evaluation differed significantly and the differ-
ence is characterized by a very low level of significance of
p <0.0001, which means that in subsequent measurements
the measured antibody level was significantly different.Table 2 Geometric mean antibody concentration and standar
weight in the individual periods of the study: prior to the first dose
injection (III) and 4 weeks after the boost (IV).
Group Serotype/
study period
Tp. 4 Tp.
Group I (birth
weight <1000 g)
I Geometric mean 0.081 0.26
SD 0.09 0.28
II Geometric mean 2.141 1.15
SD 2.58 2.47
III Geometric mean 0.463 0.90
SD 0.47 1.35
IV Geometric mean 2.835 6.49
SD 4.55 8.64
Group II (birth
weight 1000 g)
I Geometric mean 0.093 0.43
SD 0.32 0.62
II Geometric mean 1.589 0.91
SD 2.01 2.42
III Geometric mean 0.337 0.96
SD 0.29 1.30
IV Geometric mean 2.661 10.7
SD 4.05 20.2Comparison of mean values indicates that a significant in-
crease in antibody level between the period prior to
vaccination (Measurement I) and the measurement per-
formed following administration of three doses of the
vaccine (Measurement II), followed by a decrease between
the third dose and the booster dose (Measurement III).
After the last dose, an increase was observed once again
(Measurement IV). Measurements II and IV were also
significantly different from each other. Only the mean
concentration of antibodies for serotype 6B in children with
birth weight >1000 g rose slightly prior to the administra-
tion of the booster dose compared to the primary immu-
nization, but the difference was not statistically significant.
Statistical analysis of the two groups during the whole study
showed that there were no significant differences between
the groups.
Table 3 presents the comparison of the groups in terms
of the percentage of infants who had antibody concentra-
tions 0.35 mg/mL, for different serotypes and for all pe-
riods of the study. Prior to the administration of the
vaccine, the concentration of 0.35 mg/mL was noted in
individual cases only. The majority of children in both the
primary series, as well as after the booster dose, achieved
an antibody level 0.35 mg/mL, with no significant differ-
ences between the groups. One month after administration
of the third dose of the vaccine the ratio was 90.7% of
children in Group I and 91.1% of children in Group II. In both
groups, serotypes 6B and 23F were the least immunogenic.
Differences between groups were not statistically signifi-
cant. The antibody level of 0.35 mg/mL was achieved by
78.3% of children for the serotype 6B, and by 87% of pa-
tients for the serotype 23F in Group I. In Group II, the
percentages for these two serotypes were even lower. In
the period between the administration of the primary
vaccination and the booster dose, a significant decrease in
the antibody level and reduction in the number of childrend deviation (SD) in the evaluated groups based on the birth
of PCV7 (I), 4 weeks after three doses (II), prior to the booster
6b Tp. 9V Tp. 14 Tp. 18C Tp. 19F Tp. 23F
2 0.083 0.319 0.094 0.175 0.132
0.12 0.65 0.13 0.16 0.14
5 2.272 5.371 1.852 2.562 1.219
2.84 8.48 1.91 1.68 1.44
3 0.562 2.621 0.476 0.846 0.621
1.22 4.56 0.53 3.77 0.82
4 4.701 15.255 3.834 3.526 4.988
6.71 22.44 3.90 9.82 5.11
6 0.131 0.493 0.078 0.261 0.162
0.18 2.29 0.14 0.28 0.19
6 1.566 3.559 1.562 2.428 0.892
1.93 6.22 1.89 2.59 2.07
1 0.415 1.667 0.421 1.042 0.666
0.31 13.91 0.76 5.32 0.51
91 4.707 14.853 3.132 5.749 6.230
6 4.88 23.55 4.76 6.94 8.69
Figure 1 Serotype specific response to pneumococcal antigens, prior to the first dose of PCV7, 4 weeks after three doses, fol-
lowed by a booster dose and 4 weeks after the boost in both groups of children: Group I <1000 g, Group II 1000 g. The graph
depicts the geometric mean  standard deviation (SD) concentration of antibodies.
104 E. Szynczewska, D. Chlebna-Soko´1with protective levels of antibodies were observed. How-
ever, it was noted that titers of some serotypes remained
over that value. Following administration of the booster
dose, almost all children who completed the study achieved
an antibody level of 0.35 mg/mL for all serotypes.4. Discussion
IPD remains one of the most serious human bacterial in-
fections and vaccinations against it are not widely available(in Poland they are available free of charge only for children
in risk groups). Therefore, promotion of antipneumococcal
vaccination seems extremely important. Our last publication
evaluated the immune response following administration of
the PCV7 vaccine to 40 premature children, based on their
gestational age.15 This time we decided to focus on birth
weight as a factor influencing response rates. The previously
conducted research on the pneumococcal conjugate vaccine
confirmed its effectiveness and high immunogenicity, but
mainly to children born after the 37th week of preg-
nancy.13,14,23 For that reason, in our studywedid not create a
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Immunogenicity of PCV7 in LBW preterms 105control group consisting of children born at term. One study
evaluated response to the PCV7 vaccine in children bornwith
very low and extremely low birth weight.19 Other authors
focused primarily on the question of how duration of preg-
nancy influenced the immunogenicity of PCV7.16e18 In this
study we used the heptavalent pneumococcal vaccine, as at
the time of the study it was the only vaccine approved for
children aged<2 years. Recently, 10- and 13-valent vaccines
have been authorized. However, in accordance to the
criteria adopted by WHO for assessment and registration of
new vaccines, these vaccines are evaluated by a comparison
of their immunogenicity to the immunogenicity of the PCV7
vaccine.24 Despite the fact that the 13-valent vaccinednot
the heptavalent onedis currently used, those results are
very important. Postvaccination immunological response
based solely on the quantitative determination of antibody
concentration was also recommended as sufficient for the
timewhen we had begun this study. Since 2008, theWHO has
also recommended qualitative antibody assessment
methods.25,26
Data obtained here indicate that following administra-
tion of three doses of the vaccine, 91% of patients in Group I
and Group II reached antibody concentrations 0.35 mg/
mL, which is considered protective by WHO.27 Following
administration of the booster dose the rate was 100%.
These results are similar to those reported in other studies,
including children born at term, according to which the
concentration of postvaccination antibodies offering pro-
tection against the invasive infection is between 82% and
100%.12,18 It should be noted that the interval between the
third and fourth dose of the vaccine (10 months in this
study) was associated with increased number of infants
with antibody levels <0.35 mg/mL. The observation con-
firms the need for a full course of vaccination, but also
draws attention to the need of early administration for the
booster dose. Literature data indicate that children be-
tween the primary vaccination and the last dose of vaccine
are at the highest risk of IPD.28 That is a very important
observation because in Polandddespite the recommenda-
tions of the Polish Working Group for IPD stating that the
booster should be given at age 13e15 months29dthe
vaccination is usually administered at age 16e18 months,
along with other routine vaccinations.30
Serotypes 6B and 23F proved to be the least immuno-
genic following the primary vaccination, although the dy-
namics of decline of antibodies for the serotype 6B were
the lowest. Similar results were obtained by D’Angio et al19
in the study comparing two groups of children with very low
birth weight; better response to the vaccine was presented
by children with the birth weight of 1001e1500 g (6B,
91.3%; 23F, 94.4%), than by those with birth weight <1000 g
(6B, 76.7%; 23F, 79.4%).19 In our study, the differences
between groups were not statistically significant even if
children with birth weight over 1500 g were also included in
Group II. It is worth mentioning that, in the majority of
published studies regarding both preterm and term chil-
dren, those serotypes were the least immunogenic
following the primary vaccination.16e18,31,32 For other se-
rotypes, no significant differences between the two
analyzed groups (children born with birth weight <1000 g
and 1000 g) were noted. Taking into account the fact that
in Poland the vaccination of children born prematurely is
106 E. Szynczewska, D. Chlebna-Soko´1often unduly delayed, this analysis could contribute to
earlier vaccination.30
During the study, PCV7 was administered according to the
scheme imposed by the Polish Immunization Schedule, which
meant at the ages of 2 months, 3 months, 4 months, and 16
months, if no contraindications were present. In cases where
the first vaccination was deferred (due to contraindications),
another was carried out according to the scheme. In cases of
extreme prematurity, vaccination was started at the end of
the fifth month of life. However, as in a similar paper,19 we
have not observed that children who started the series of
vaccination later achieved lower antibodies levels.
In conclusion, children born prematurely with low and
extremely low body weight reached optimal levels of an-
tibodies after vaccination against Pneumococcus. It seems
to be more immunogenic in Polish infants than in other
western infants. We also observed that the least immuno-
genic serotypes were 6B and 23F. At the same time the
highest concentration of antibodies was obtained for the
serotype 14, which is the most often isolated in pneumo-
coccal infection in Polish children. The results confirm the
need for vaccination of preterm children.
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